Myovant Sciences PE Ratio 2017-2021 | MYOV

Current and historical p/e ratio for Myovant Sciences (MYOV) from 2017 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Myovant Sciences PE ratio as of January 25, 2022 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Myovant Sciences PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-01-26 13.05 0.00
2021-09-30 22.44 $-2.61 0.00
2021-06-30 22.77 $-3.13 0.00
2021-03-31 20.58 $-2.83 0.00
2020-12-31 27.62 $-2.67 0.00
2020-09-30 14.05 $-2.81 0.00
2020-06-30 20.62 $-2.85 0.00
2020-03-31 7.55 $-3.37 0.00
2019-12-31 15.52 $-3.71 0.00
2019-09-30 5.20 $-3.79 0.00
2019-06-30 9.05 $-3.99 0.00
2019-03-31 23.87 $-4.08 0.00
2018-12-31 16.41 $-3.82 0.00
2018-09-30 26.55 $-3.48 0.00
2018-06-30 22.87 $-2.99 0.00
2018-03-31 21.27 $-2.40 0.00
2017-12-31 12.64 $-1.96 0.00
2017-09-30 15.47 $-1.41 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.222B $0.059B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $138.639B 8.76
Bio-Rad Laboratories (BIO.B) United States $16.992B 34.48
QIAGEN (QGEN) Netherlands $10.895B 18.45
Biohaven Pharmaceutical Holding (BHVN) United States $7.620B 0.00
Emergent Biosolutions (EBS) United States $2.497B 8.98
Arcus Biosciences (RCUS) United States $2.167B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.110B 0.00
Zymeworks (ZYME) Canada $0.466B 0.00
SQZ Biotechnologies (SQZ) United States $0.206B 0.00
Ambrx Biopharma (AMAM) United States $0.195B 0.00
Enzo Biochem (ENZ) United States $0.157B 20.19